Synopsis:
Lupin has strengthened its U.S. generics portfolio with the launch of Loteprednol Etabonate Ophthalmic Suspension 0.5%. Backed by a 71% profit surge, the company is aggressively expanding its global footprint, leveraging complex generics and specialty products for sustained momentum.
One of India’s leading pharmaceutical exporters has further expanded its U.S. portfolio with the launch of a new ophthalmic product. The development is expected to strengthen the company’s position in the lucrative U.S. generics market, even as it continues to post strong financial growth supported by a solid global presence.
The company in focus is Lupin Limited, which currently holds a market capitalization of Rs. 89,288 crore. The stock opened today at Rs. 1,938, slightly higher than its previous close of Rs. 1,930.10, and climbed to an intraday high of Rs. 1,961.60, reflecting a modest gain of approximately 1.63 percent.
What’s the News?
Lupin has announced the launch of Loteprednol Etabonate Ophthalmic Suspension 0.5 percent in the United States. This product is a generic version of Bausch & Lomb’s Lotemax Ophthalmic Suspension 0.5 percent. It is indicated for the treatment of steroid-responsive inflammatory conditions affecting various parts of the eye, including the conjunctiva, cornea, and anterior segment. The U.S. launch is strategically important for Lupin as the ophthalmic therapeutic segment presents stable demand, and Lotemax generated annual sales of approximately USD 55 million in the U.S.
Financial Snapshot
Lupin has demonstrated significant growth across key financial parameters for the period between March 2024 and March 2025. Revenue from Operations increased from Rs. 20,011 crore to Rs. 22,708 crore, reflecting a growth of approximately 13.5 percent. Operating profit grew from Rs. 3,800 crore to Rs. 5,283 crore, a rise of around 39 percent.
Profit before tax (PBT) surged from Rs. 2,422 crore to Rs. 4,015 crore, marking an increase of 65.8 percent. Net profit jumped from Rs. 1,936 crore to Rs. 3,306 crore, recording a robust growth of 70.8 percent.
Borrowings also increased from Rs. 2,922 crore to Rs. 5,448 crore, supporting expansion activities. Total assets expanded from Rs. 23,751 crore to Rs. 29,205 crore, registering a growth of approximately 23 percent. Additionally, net cash flows turned positive, rising from a negative Rs. (248) crore to Rs. 560 crore. Lupin’s financial health remains solid, with a stock P/E of 27.2, ROCE of 21.5 percent, ROE of 20.8 percent, and ROA of 12.5 percent. The Debt-to-Equity ratio is maintained at a comfortable 0.32, and the dividend payout stands at 16.7 percent.
Also read: Steel stock crashes after reporting weak Q1 results with 45% YoY decline in net profit
About the Company
Lupin Limited, headquartered in Mumbai, is a global pharmaceutical leader with a presence in over 100 countries. The company’s diverse portfolio includes branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It holds a strong position in multiple therapeutic areas including respiratory, cardiovascular, anti-diabetic, anti-infective, and women’s health. With a dedicated workforce of over 23,000 professionals, Lupin is committed to advancing healthcare outcomes through its subsidiaries Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Strategic Outlook and Other Information
Lupin’s compounded profit growth over the last three years stands at an impressive 60 percent. The company continues to focus on high-margin complex generics and specialty products, particularly in the U.S. market, which remains a significant revenue driver. With 15 state-of-the-art manufacturing facilities and seven research centers globally, Lupin is well-positioned to navigate regulatory landscapes and competitive pressures.
Written by – Manan Gangwar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Pharma stock in focus after it launches anti inflammation drug in US market appeared first on Trade Brains.